Aegros

What Aegros does

Aegros is an Australian biopharmaceutical company headquartered in Macquarie Park, New South Wales, that develops, manufactures and licenses plasma-derived medicinal products using its proprietary HaemaFrac® electric-field plasma fractionation technology. Founded in 2017 by Professor Hari Nair and John Manusu, the company operates a TGA-GMP-licensed Macquarie Park facility (with HF-01 and the newer HF-02 machines ranging from 30,000 to 150,000 litres of annual plasma processing capacity) and is constructing a 1,000,000-litre Springfield, Queensland facility expected online in 2026. Its current commercial lead product is Covimmune™, a COVID-19 hyperimmune immunoglobulin that demonstrated fourfold higher antibody titers than convalescent plasma in the CHAT clinical trial; the product pipeline also spans hyperimmunes (Anti-D, RIG, TIG, CMV IG, HBIG, VZV IG), clotting factors (FVIII, FIX, FX, FXIII, PCC) and plasma proteins (IVIG, Albumin, Antithrombin III, Fibrinogen, C1 Inhibitor).

The company's business model combines three distinct go-to-market paths: Builds & Operates (owning and running its own facilities), Build & Transfer (technology licensing and engineering), and Build-Operate-Transfer (three-year operation before client handover), alongside toll-manufacturing services. In Australia, plasma-derived products are sold through the National Blood Authority as the sole procurement channel, while internationally, the company pursues technology licensing to major biopharmaceutical firms and partners with blood collection organizations. Through the August 2023 US$400M Royal Group Plasma Fractionation joint venture with Royal Group (Cambodia) and Fresh Start Australia, Aegros is establishing a 1,000,000-litre fractionation plant in Singapore with a sterile fill/finish facility in Phnom Penh, targeting Asian plasma currently being discarded due to the inability of legacy Cohn methods to process it under developed-market regulatory standards.

Following a November 2024 operational stand-down triggered by approximately AU$16M of unpaid creditors, Aegros secured an AU$37M rescue package in mid-2025 led by property developer Ray Nolan's investment syndicate, overhauled its board and executive team (appointing Damian Thornton as CEO, Nolan as Chairman, James Clyne as CFO and four new Non-Executive Directors), and was continuing toward an IPO on the ASX at the time of disclosure. The company is preparing its first commercial product listings (COVID-19 hyperimmune via NBA's Bloodstar system) and is positioning HaemaFrac as a structural alternative to the 70-year-old Cohn cold ethanol fractionation method, claiming roughly twice the therapeutic yield per litre of plasma, elimination of ethanol/methanol processing, lower energy consumption, and retention of IgG3 subclasses lost in conventional methods.

Name

Aegros

Legal name

Aegros

Website

https://aegros.com.au

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Aegros is an Australian biopharmaceutical company that develops, manufactures and licenses plasma-derived medicinal products — including a COVID-19 hyperimmune and a pipeline of hyperimmunes, clotting factors, IVIG and albumin — using its proprietary HaemaFrac® electric-field plasma fractionation technology.

Ownership category

akta.pro rank

Product category

Plasma-derived Biopharmaceuticals

akta.pro primary industry

Plasma Fractionation & Purification Manufacturing (HLAIAHAI)

akta.pro secondary industry

Plasma-Derived & Blood Products Distributors (HLAIAJAJ)

Keywords

• Plasma fractionation technology
• Plasma-derived medicines
• Hyperimmune globulins
• Biopharmaceutical manufacturing
• Therapeutic plasma products

Headquarters

HQ city

Port Macquarie

HQ country

Australia

HQ region

Oceania

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. COVID-19 Hyperimmune Sales: Once TGA ARTG listing is achieved (expected Q3/Q4 2024), Aegros will sell its COVID-19 hyperimmune product through the National Blood Authority ordering system in Australia. This represents the company's first commercial revenue stream.
2. Licensing Agreements: As the only technology of its kind, HaemaFrac can generate recurring revenue through licensing agreements with major biopharmaceutical companies for use of the technology in their facilities.
3. Partnership and Co-development Revenue: Modular design and adaptability make HaemaFrac ideal for partnerships with plasma collection centers and research facilities focused on innovative therapeutic applications, generating partnership and co-development revenue.
4. Toll Manufacturing: Aegros can utilize its HaemaFrac facility for toll manufacturing therapeutic plasma products for less developed countries, generating sales while optimizing the HaemaFrac process. This began around August/September 2024.
5. Plasma Derived Medicinal Products: Future production and sales of albumin, IVIG, and other plasma products from the 1 million litre facility in Springfield, Queensland (expected online 2026). Products include hyperimmune globulins (Anti-D, RIG, TIG, CMV IG, HBIG, VZV IG) and clotting factors.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Aegros is an Australian biopharmaceutical company that manufactures plasma-derived medicinal products using its proprietary HaemaFrac® electric field-based plasma fractionation technology. The company fractionates human plasma into specialty therapeutic proteins including hyperimmune globulins, clotting factors, albumin, and immunoglobulins. Aegros also licenses its HaemaFrac® technology to other biopharmaceutical companies and offers engineering, build-operate-transfer, and toll manufacturing services for plasma fractionation facilities globally.

Product overview

Aegros is an Australian biopharmaceutical company offering a portfolio of plasma-derived medicinal products powered by its proprietary HaemaFrac® plasma fractionation technology. The HaemaFrac® process serves as the core technology platform, using electric field-based separation to fractionate plasma into specialty medicinal proteins including immunoglobulins, albumin, and clotting factors. The company operates multiple HaemaFrac® machines (HF-01 with 30,000L/year capacity and HF-02 with 150,000L/year capacity) and manufactures hyperimmune products such as Covimmune™ (COVID-19 hyperimmune), Anti-D, Rabies Immunoglobulin, Tetanus Hyperimmune, CMV IG, Hepatitis B IG, and VZV IG. The product portfolio also includes plasma proteins such as Factor VIII, Factor IX, Factor X, Factor XIII, PCC, Immunoglobulin, Antithrombin III, Fibrinogen, C1 Inhibitor, and Albumin. Aegros operates through three business models: Builds & Operates (owning facilities), Build & Transfer (technology licensing), and Build, Operate & Transfer (3-year operation before handover). The company is constructing a 1 million liter facility in Springfield, Queensland and a joint venture 1 million liter facility in Singapore with Cambodia fill-finish operations.

Differentiator

Problem solved

Functional benefit

Brands

• Haemafrac: Proprietary plasma fractionation technology using electric field to isolate plasma proteins with high yield and purity.
• Covimmune
• HF-01
• HF-02

Products and services

• HaemaFrac® Plasma Fractionation Technology (Licensing) Proprietary electric field-based plasma fractionation technology using ion mobility and membrane separation to isolate plasma proteins. Licensed to biopharmaceutical companies for use in their own manufacturing facilities. Achieves over 85% process yield (vs 40-50% for traditional Cohn method), eliminates hazardous chemicals, and reduces energy consumption.
• HF-02 HaemaFrac® Machine Next-generation HaemaFrac® plasma fractionation machine featuring 8 cartridges with capacity to process up to 150,000 liters of plasma per year, a 5x improvement over the HF-01 model. Used for commercial-scale hyperimmune production.
• Covimmune™ (COVID-19 Hyperimmune) Hyperimmune immunoglobulin product derived from COVID-19 convalescent plasma using HaemaFrac® technology. Provides passive immunity for immunocompromised individuals unable to benefit from vaccines. Demonstrated 685 AU/mL antibody levels vs 154.7 AU/mL for convalescent plasma in clinical trials.
• Toll Manufacturing Services Contract manufacturing of therapeutic plasma products using HaemaFrac® facility for developing countries and partners needing plasma fractionation capacity.
• Build, Operate & Transfer (BOT) Fractionation Facility Service Full-service plasma fractionation facility delivery model where Aegros provides technology, engineering, and training; client funds capital expenditure; Aegros operates the plant for 3 years before transferring to the client. Designed for governments and health systems seeking to establish domestic plasma fractionation capability.

Quantifiable outcome

• HaemaFrac produces approximately twice the therapeutic yield per liter of plasma compared to Cohn fractionation
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered minor and core.

• Dave SharmaminorOthers · 23 November 2023Strategic Advisory Committee Chairman. Former Australian Ambassador to Israel and Federal Member for Wentworth. Provides expert advice in government relations and offshore business development.
• Jan BultminorOthers · 23 November 2023Strategic Advisor. Established and was President of Plasma Protein Therapeutics Association (PPTA) for 23 years. Provides deep plasma sector experience and therapeutic plasma industry expertise.
• Dr Erin EvansminorOthers · 23 November 2023Strategic Advisor. CEO of Life Sciences Queensland, the peak life sciences body in Queensland. Provides advice on Queensland Government engagement and life sciences research/corporate community.
• Ernst & Young (EY)minorOthers · 25 August 2023Appointed as Aegros' auditors replacing Hall Chadwick, effective for 2022-23 audit. Appointment made as part of IPO preparation to bring bioPharma sector expertise.
• Royal Group (Cambodia)coreStrategic or Co-development Partner · 7 August 2023Historic US$400 million joint venture to build 1 million litre HaemaFrac facility in Singapore with sterile fill/finish in Cambodia. The Royal Group Plasma Fractionation (RGPF) joint venture will process Asian plasma currently being discarded, creating world-first fractionation capability for local plasma in the region.
• Fresh Start AustraliacoreStrategic or Co-development Partner · 7 August 2023Strategic partner in Royal Group Plasma Fractionation joint venture. Fresh Start Australia is one of Aegros' largest backers and an Indigenous-owned investment company. Provides strategic partnership to help the business reach its full potential.
• Dr Ranjeet S. AjmaniminorOthers · 6 July 2023Appointed CEO of Aegros Asia. Known as father of India's blood plasma industry. Provides academic, commercial, and policy expertise for plasma fractionation programs across South-East Asia. Based in Singapore.
• Queensland GovernmentcoreStrategic or Co-development Partner · 1 November 2022Invested In Queensland program supporting construction of 1 million litre HaemaFrac facility in Springfield, southwest of Brisbane. Project worth over $350 million creating approximately 350 high-skilled jobs in first four years of operations. Expected online 2026.
• Australian Red Cross LifebloodcoreStrategic or Co-development Partner · 1 February 2021Lifeblood agreed to supply plasma for Covimmune COVID-19 hyperimmune manufacturing. Partnership secured critical plasma supply for clinical trial and commercial production.
• National Blood AuthoritycoreChannel Partner/ Reseller/ DistributorNBA is the sole purchaser of plasma-derived medicinal products in Australia. Aegros is engaging with NBA to ensure smooth entry onto its Bloodstar product ordering system once ARTG listing is achieved.

Scale indicators13 records

Recent moves11 records

Expansion highlights8 records

Broad incumbents

• CSL Behring (CSL Limited): Australian-headquartered global leader in plasma-derived therapies (immunoglobulins, albumin, clotting factors). Directly overlaps with Aegros' product portfolio and home market, at vastly larger scale.
• Grifols: Global plasma fractionator producing immunoglobulins, albumin and clotting factors with its own collection network. Core incumbent competitor whose Cohn-based economics HaemaFrac aims to disrupt.
• Takeda (Plasma-Derived Therapies): Major plasma-derived therapy producer (via Baxalta/Shire) across immunoglobulins and hyperimmunes. Competes in the same therapeutic categories Aegros targets.
• Octapharma: Privately held global manufacturer of human protein plasma products. Direct incumbent in the fractionation and hyperimmune space Aegros is entering.
• Kedrion Biopharma: Plasma products company specializing in immunoglobulins and hyperimmunes; notably acquired the founders' earlier Life Therapeutics business, making it a close category and lineage peer.
• Biotest AG: German plasma protein manufacturer producing immunoglobulins, clotting factors and albumin. Overlaps directly with Aegros' plasma-derived product categories.

Emerging players

• ADMA Biologics: Focused developer/manufacturer of specialty plasma-derived hyperimmune immunoglobulins. Comparable in size ambition and product focus on hyperimmune globulins like Aegros' Covimmune.
• Emergent BioSolutions: Produces hyperimmune/plasma-derived products (e.g., anthrax and other immune globulins). Comparable focus on hyperimmune therapeutics and government-purchaser markets.
• Liminal BioSciences (formerly Prometic): Developed alternative plasma-protein purification technology (PPPS) as a non-Cohn fractionation approach. Closest technology-differentiated peer to HaemaFrac's novel method.

Regional players

• PrIME Biologics: Singapore-based plasma fractionation company from which Aegros acquired the HaemaFrac plant/IP; operates the same technology lineage in Asia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@aegros
• LinkedInlinkedin.com/company/aegros
• Xx.com/aegros_ltd

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aegros